Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD38 | P28907 | 15/20 | 0.55 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.39 |
| ▸ | BMPR1A | P36894 | 2/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.39 |
| ▸ | ACVRL1 | P37023 | 2/20 | 0.39 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23329162 | 0.87 | CD38 (0.75) | CD38 | |
| SCHEMBL23329886 | 0.84 | CD38 (0.57) | CD38KDM4ETSHRHTTGRIN2B | |
| SCHEMBL23305001 | 0.83 | CD38 (0.58) | CD38KDM4ETSHRHTT | |
| SCHEMBL23329533 | 0.82 | CD38 (0.73) | CD38BMPR1BBMPR1ATGFBR1ACVRL1 | |
| SCHEMBL23329449 | 0.81 | CD38 (0.58) | CD38BMPR1BBMPR1ATGFBR1ACVRL1 | |
| SCHEMBL23304846 | 0.77 | CD38 (0.58) | CD38 | |
| SCHEMBL23329431 | 0.76 | CD38 (0.60) | CD38 | |
| SCHEMBL23306265 | 0.74 | CD38 (0.56) | CD38 | |
| SCHEMBL23304751 | 0.72 | CD38 (0.85) | CD38HTT | |
| SCHEMBL23329185 | 0.71 | CD38 (0.86) | CD38 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021087087-A1 | N-CYCLOHEXYL-5-(THIAZOL-5-YL)-1H-INDOLE-7-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS CD38 INHIBITORS FOR INCREASING NAD+ AND FOR THE TREATMENT OF E.G. MUSCULAR DISORDERS | MITOBRIDGE INC. (US) | 2021-05-06 | — | — | WO | disclosed |